References of "Gharbi, Myriam"
     in
Bookmark and Share    
Full Text
See detailBiomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
Henrotin, Yves ULg; Gharbi, Myriam; DEBERG, Michelle ULg et al

Patent (2014)

Detailed reference viewed: 12 (4 ULg)
Full Text
Peer Reviewed
See detailIdentification of differential pattern of protein expression in canine osteoarthritis serum after anterior cruciate ligament transection: a proteomic analysis.
Gharbi, Myriam; Sanchez, Christelle ULg; Mazzucchelli, Gabriel ULg et al

in Veterinary journal (London, England : 1997) (2013), 197(3), 848-53

Osteoarthritis (OA) management remains a great challenge and there is considerable effort to understand its pathophysiology and to identify new therapeutic targets and biomarkers. Canine OA surgically ... [more ▼]

Osteoarthritis (OA) management remains a great challenge and there is considerable effort to understand its pathophysiology and to identify new therapeutic targets and biomarkers. Canine OA surgically induced by the transection of the anterior cruciate ligament (ACLT) is a widely used and relevant model. This study reports a proteome mapping of dog serum and an analysis of the differentially expressed proteins between before and after ACLT. In the first part of the study, 261 picked protein spots were identified from preparative 2D gels and 71 different proteins were identified among the 261 spots present on the reference map. Canine serum proteome mapping reveals the presence of proteins of interest, such as fetuin B, complement C3 and C1s and pregnancy zone protein. The comparison between serum from dogs before and after ACLT reveals the differential expression of several proteins that could play a key role in the pathogenesis of OA. A number of proteins, such as fetuin B and complement C3, were increased in dog OA serum whereas others, such as hyaluronan binding protein 2, inter-alpha-trypsin inhibitor H4 (ITIH4), complement C1s and C4 and haptoglobin were decreased. Some of these proteins could be candidate biomarkers for diagnosis, prognosis and treatment evaluation. The results of the study also reinforced the similarities between dog experimental OA and human cases of OA. [less ▲]

Detailed reference viewed: 11 (1 ULg)
Full Text
Peer Reviewed
See detailFibulin 3 peptides Fib3-1 and Fib3-2 are potential biomarkers of osteoarthritis.
Henrotin, Yves ULg; Gharbi, Myriam; Mazzucchelli, Gabriel ULg et al

in Arthritis and Rheumatism (2012), 64(7), 2260-7

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis ... [more ▼]

OBJECTIVE: This study was undertaken to identify new biomarkers of osteoarthritis (OA) by proteomics analysis and to develop specific immunoassays to detect and quantify them. METHODS: Proteomics analysis was performed in urine samples from 10 women (mean+/-SD age 76.0+/-5.0 years) undergoing knee replacement surgery due to severe OA and 5 healthy women (mean+/-SD age 25.6+/-2.6 years). Protein content was analyzed by 2-dimensional differential gel electrophoresis. Protein spots that exhibited an OA:control abundance ratio of >/=1.5 were identified by mass spectrometry. Specific enzyme-linked immunosorbent assays were developed and validated in serum obtained from 236 healthy subjects ages 20-64 years and from 76 patients with severe radiologic knee OA (mean+/-SD age 68.8+/-11.9 years). Immunohistochemical analysis was performed on articular cartilage from tibial plateaus. RESULTS: Thirteen proteins within spots that were significantly modified between groups were identified. Two peptides of fibulin 3, named Fib3-1 and Fib3-2, were of particular interest. Two antisera directed against these peptides were used to develop immunoassays. Compared with age-matched healthy subjects, median levels of serum Fib3-1 and Fib3-2 were elevated in OA patients (54.6 pM versus 85.1 pM [P<0.0001] and 144.4 pM versus 191.4 pM [P<0.0001], respectively). Using area under the receiver operating characteristic curve analysis, we demonstrated that Fib3-1 and Fib3-2 levels discriminate between OA and normal populations. Immunostaining revealed the presence of Fib3-1 and Fib3-2 in chondrocytes and in the extracellular matrix of the superficial layer of the fibrillated cartilage. CONCLUSION: Our findings indicate that Fib3-1 and Fib3-2 are potential biochemical markers for the diagnosis of OA. [less ▲]

Detailed reference viewed: 23 (6 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 16 (7 ULg)
Full Text
See detailBIOMARKER FOR OSTEOARTHRITIS AND/OR OTHER AGEING-RELATED DISEASES, AND USE THEREOF
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2011)

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications ... [more ▼]

The invention relates to the identification of abiomarker whose abundance in biological sampleis changed in subjects with osteoarthritis and/or other ageing-related diseases. Thebiomarker hasapplications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 17 (6 ULg)
Full Text
Peer Reviewed
See detailL’interleukine-1β augmente le catabolisme de la fibuline-3 par les chondrocytes : démonstration in vitro par la mesure des fragments Fib3-1 et Fib3-2
Gharbi, Myriam; Legrand, Catherine; Sanchez, Christelle ULg et al

in Revue du Rhumatisme (2011), 78(suppl 5), 131-132

Detailed reference viewed: 38 (18 ULg)
Full Text
Peer Reviewed
See detailApplication for proteomic techniques in studying osteoarthritis: a review
Gharbi, Myriam; Deberg, Michelle ULg; Henrotin, Yves ULg

in Frontiers in Physiology (2011), 2(90), 1-11

Detailed reference viewed: 18 (5 ULg)
Full Text
See detailBiomarker for osteoarthritis and/or other ageing-related diseases, and use thereof
Henrotin, Yves ULg; Gharbi, Myriam; Deberg, Michelle et al

Patent (2009)

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications ... [more ▼]

The invention relates to the identification of a biomarker whose abundance in bodily fluids is changed in subjects with osteoarthritis and/or other ageing-related diseases. The biomarker has applications in the diagnosis of osteoarthritis and/or other ageing-related diseases, in determining the prognosis for an individual diagnosed with osteoarthritis and/or other ageing-related diseases, and in monitoring the efficacy of treatment for osteoarthritis and/or other ageing-related diseases. [less ▲]

Detailed reference viewed: 13 (4 ULg)